The JOINT Study :Evaluation of effect and safty of Losartan/Hydrochlorothazide fixed dose combination for hypertensive patients

The JOINT Study :Evaluation of effect and safty of Losartan/Hydrochlorothazide fixed dose combination for hypertensive patients - The JOINT Study The Jikei Optimal Anti-hypertension Treatment Study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001950

Enrollment

400

Registered

2009-05-08

Start date

2008-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

Losartan/Hydrochlorothizide

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Hypertensive patients, whose blood pressure has not been reached the target levels SBP>130mmHg or DBP>80mmHg. (2)Patients who have been treated by 1 to 3 antihypertensive drugs. (3)Outpatients (4)Men and women aged 20 to 75 years

Exclusion criteria

Exclusion criteria: (1)Patiens with renal failure(serum creatinine >2.5 mg/dL (2)Patients with liver dysfunction [GPT(ALT) over three times the normal value] (3)Pregnant or possible pregnant women (4)Breast-feeding women (5)Patients who are considered not eligible for the study by the attending doctor due to medical reasons

Design outcomes

Primary

Measure	Time frame
Change in systolic and diastolic blood pressure after 3 months of treatment	—

Secondary

Measure	Time frame
Change in home blood pressure, serum uric acid, microalbuminuria, BNP after 3 months of treatment Change in serum uric acid, microalbuminuria, BNP, medication cost after 6 months of treatment	—

Countries

Japan

Contacts

Public ContactIwao Ohno

Jikei University School of Medicine Division of Kidney and Hypertension

i-ohno@jikei.ac.jp03-3433-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026